The ratio places HER2 signal counts in relation to the number of chromosome 17 centromere signals within tumor cells. This comparison helps determine whether increased HER2 dosage reflects changes at the HER2 locus or a broader change involving chromosome 17. Consequently, the ratio provides a more informative interpretation than HER2 copy number alone, particularly when gene and chromosome counts both increase.
Analysts interpret HER2 signals alongside chromosome 17 centromere signals rather than treating every increase in HER2 copies as amplification. A disproportionate rise in HER2 relative to the centromere supports locus-specific amplification, whereas parallel increases may indicate increased chromosome 17 copies. This distinction clarifies the genomic basis of an abnormal dosage result and supports disease classification.
Borderline results can arise when HER2 copy number and chromosome 17 signals increase together, making the underlying dosage change less obvious. Examining both measurements and their calculated ratio helps resolve whether the finding reflects HER2-focused amplification or broader chromosome-level gain. Such quantitative interpretation is important when genomic evidence may influence classification or consideration of targeted treatment.
The assay uses labeled probes directed to the HER2 locus and the chromosome 17 centromere in interphase tumor-cell nuclei. Analysts identify and count the respective signals, then calculate HER2 copy number and the HER2-to-centromere ratio. These linked measurements are interpreted together to characterize abnormal gene dosage rather than relying on a single signal count.
In relevant cancers, the results can help identify patients whose tumors may benefit from HER2-targeted therapy. The assay contributes quantitative evidence about HER2 dosage and distinguishes amplification from increased chromosome 17 copies, allowing treatment-related interpretation to reflect the tumor’s genomic pattern instead of an isolated increase in HER2 signals.
HER2 copy number, chromosome 17 number, and their relationship provide measurable genomic features for studying tumor biology. Researchers can correlate these abnormalities with disease classification and examine how altered gene dosage relates to tumor characteristics. The quantitative format also supports comparisons among tumors with locus-specific amplification, broader chromosome changes, or less clearly defined dosage patterns.